12/27
11:24 am
exel
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
12/25
01:54 pm
exel
EXEL vs. INCY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]
Low
Report
EXEL vs. INCY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]
12/23
10:31 am
exel
Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024? [Yahoo! Finance]
Low
Report
Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024? [Yahoo! Finance]
12/23
08:00 am
exel
Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Brookline Capital Management. They set a "buy" rating on the stock.
Low
Report
Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Brookline Capital Management. They set a "buy" rating on the stock.
12/20
08:22 am
exel
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? [Yahoo! Finance]
12/20
07:36 am
exel
Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $40.00 price target on the stock, up previously from $36.00.
Low
Report
Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $40.00 price target on the stock, up previously from $36.00.
12/18
05:35 pm
exel
Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight [Yahoo! Finance]
Low
Report
Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight [Yahoo! Finance]
12/17
08:05 am
exel
Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024 [Yahoo! Finance]
Low
Report
Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024 [Yahoo! Finance]
12/17
08:02 am
exel
Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $39.00 price target on the stock, up previously from $35.00.
Low
Report
Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $39.00 price target on the stock, up previously from $35.00.
12/17
08:00 am
exel
Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024
Low
Report
Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024
12/12
05:36 am
exel
Ryvu Therapeutics provides an update on RVU120 Phase II program [Yahoo! Finance]
Low
Report
Ryvu Therapeutics provides an update on RVU120 Phase II program [Yahoo! Finance]
12/10
08:14 am
exel
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? [Yahoo! Finance]
Low
Report
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? [Yahoo! Finance]
12/9
12:52 pm
exel
EXEL or INCY: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Low
Report
EXEL or INCY: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
12/6
01:00 pm
exel
Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
12/5
08:10 am
exel
Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF) [Yahoo! Finance]
Low
Report
Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF) [Yahoo! Finance]
12/5
05:03 am
exel
Buy The Post-Election Healthcare Dip With These Stocks [Seeking Alpha]
Low
Report
Buy The Post-Election Healthcare Dip With These Stocks [Seeking Alpha]
12/4
08:22 am
exel
Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar? [Yahoo! Finance]
Low
Report
Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar? [Yahoo! Finance]
11/29
12:04 pm
exel
Here's Why Exelixis (EXEL) is a Strong Momentum Stock [Yahoo! Finance]
Low
Report
Here's Why Exelixis (EXEL) is a Strong Momentum Stock [Yahoo! Finance]
11/28
01:42 pm
exel
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Low
Report
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
11/27
04:05 pm
exel
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
Low
Report
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
11/27
01:17 pm
exel
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion [Yahoo! Finance]
Low
Report
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion [Yahoo! Finance]
11/27
03:05 am
exel
Zacks Investment Ideas feature highlights: InterDigital, Futu and Exelixis [Yahoo! Finance]
Low
Report
Zacks Investment Ideas feature highlights: InterDigital, Futu and Exelixis [Yahoo! Finance]
11/26
04:14 pm
exel
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors [Yahoo! Finance]
Low
Report
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors [Yahoo! Finance]
11/26
04:05 pm
exel
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
Low
Report
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
11/26
02:01 pm
exel
End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL) [Yahoo! Finance]
Low
Report
End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL) [Yahoo! Finance]